From: SCUBE3 serves as an independent poor prognostic factor in breast cancer
Variable | SCUBE3 expression | p-value | ||
---|---|---|---|---|
Total | Low | High | ||
Number | 137 | 106 (77.4%) | 31 (22.6%) | |
Age, years | 55.9 ± 11.7 | 55.9 ± 11.8 | 55.7 ± 11.7 | 0.952 |
Histologic grade | 0.514 | |||
2 | 95 (69.3%) | 81 (85.3%) | 14 (14.7%) | |
3 | 42 (30.7%) | 25 (59.5%) | 17 (40.5%) | |
Histologic type | 0.399 | |||
Invasive ductal | 114 (83.2%) | 86 (75.4%) | 28 (24.6%) | |
Other | 23 (16.8%) | 20 (87.0%) | 3 (13.0%) | |
Tumor size, cm | 0.0798 | |||
≤ 2 | 55 (40.1%) | 42 (76.4%) | 13 (23.6%) | |
> 2 | 82 (59.9%) | 64 (78.0%) | 18 (22.0%) | |
Lymph node metastasis | 0.907 | |||
Negative | 72 (52.6%) | 55 (76.4%) | 17 (23.6%) | |
Positive | 65 (47.4%) | 51 (78.5%) | 14 (21.5%) | |
TMN stage | 0.0725 | |||
I | 39 (28.5%) | 30 (76.9%) | 9 (23.1%) | |
II | 52 (38.0%) | 41 (78.8%) | 11 (21.2%) | |
III | 46 (33.6%) | 35 (76.1%) | 11 (23.9%) | |
ER | 0.018 | |||
Negative | 31 (23.1%) | 19 (61.3%) | 12 (38.7%) | |
Positive | 103 (76.9%) | 55 (53.4%) | 48 (46.6%) | |
Missing | 3 | 2 | 1 | |
PR | 0.015 | |||
Negative | 24 (17.8%) | 15 (62.5%) | 9 (37.5%) | |
Positive | 111 (82.2%) | 60 (54.1%) | 51 (45.9%) | |
Missing | 2 | 1 | 1 | |
HER2 | 0.039 | |||
Negative | 109 (87.9%) | 64 (58.7%) | 45 (41.3%) | |
Positive | 15 (12.1%) | 9 (60.0%) | 6 (40.0%) | |
Missing | 13 | 11 | 2 | |
E-cadherin | 0.020 | |||
Negative | 45 (38.1%) | 30 (66.7%) | 15 (33.3%) | |
Positive | 73 (61.9%) | 62 (84.9%) | 11 (15.1%) | |
Missing Subtypes | 19 | 14 | 5 | 0.706 |
Luminal A | 79 (62.2%) | 35 (44.3%) | 44 (55.7%) | |
Luminal B | 17 (13.4%) | 9 (53.0%) | 8 (47.1%) | |
HER2 | 16 (12.6%) | 6 (37.5%) | 10 (62.5%) | |
TNBC | 25 (19.7%) | 10 (40%) | 15 (60.0%) | |
Missing | 10 | 3 | 7 | |
Recurrence | 0.855 | |||
Yes | 38 (27.7%) | 29 (76.3%) | 9 (23.7%) | |
No | 99 (72.3%) | 77 (77.8%) | 22 (22.2%) | |
Survival state | 0.032 | |||
Survival | 108 (78.8%) | 89 (82.4%) | 19 (17.6%) | |
Death | 29 (21.2%) | 12 (41.4%) | 17 (58.6%) |